Subsequent Events (Details) - Subsequent Event [member] - USD ($) |
Mar. 13, 2018 |
Jan. 25, 2018 |
Jan. 08, 2018 |
Mar. 09, 2018 |
|---|---|---|---|---|
| Statement Line Items [Line Items] | ||||
| Aggregate ordinary shares | 3,333,336 | |||
| Warrants to purchase shares | 2,500,002 | |||
| Aggregate purchase price | $ 5,000 | |||
| Total upfront and milestone payment | $ 2,200,000 | |||
| Warrants issued | 982,344 | |||
| Warrants term | The warrants may be exercised after 6 months from the date of issuance for a period of five and a half years. | |||
| Placement agent warrants [Member] | ||||
| Statement Line Items [Line Items] | ||||
| Warrants to purchase shares | 166,667 | |||
| ADS [Member] | ||||
| Statement Line Items [Line Items] | ||||
| Aggregate ordinary shares | 6,666,672 | |||
| Warrants to purchase shares | 5,000,004 | |||
| Warrant exercise price | $ 2.00 | |||
| ADS [Member] | Placement agent warrants [Member] | ||||
| Statement Line Items [Line Items] | ||||
| Warrants to purchase shares | 333,334 | |||
| Warrant exercise price | $ 2.00 | |||
| Gebro Holding [member] | ||||
| Statement Line Items [Line Items] | ||||
| Sale of milestone description | (i) €300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and €300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between €750 thousand and €1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between €300 thousand and up to €4,025 thousand upon meeting certain net sales. | |||
| Gebro Holding [member] | Euro [Member] | ||||
| Statement Line Items [Line Items] | ||||
| Total upfront and milestone payment | $ 1,500,000 | |||
| March 2014 Financing [Member] | ||||
| Statement Line Items [Line Items] | ||||
| Warrants issued | 98,234 |